Stay updated on Clinical Trial of IL-2 + Nivolumab in RCC
Sign up to get notified when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.

Latest updates to the Clinical Trial of IL-2 + Nivolumab in RCC page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe 403 error page elements were removed, including the 403 message and the error HTML snippet. The page now loads as a standard study details page with the usual header and footer.SummaryDifference0.5%

- Check15 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with an access-denied message. This indicates that the study details are not accessible at this time.SummaryDifference18%

- Check36 days agoChange DetectedThe page revision tag was updated from v3.6.5 to v3.6.6, indicating a minor underlying update to the page system rather than a content change. No user-facing content appears to be modified.SummaryDifference0.1%

- Check50 days agoChange DetectedExpanded the study record with added documentation references (Study Protocol and Statistical Analysis Plan), regulatory notes (FDA-regulated status), and data-sharing information, along with related MeSH terms. It also adds details about the investigators and their institution (Ajjai Alva, M.D., University of Michigan Rogel Cancer Center) to the collaborators section.SummaryDifference51%

- Check58 days agoChange DetectedThe study record page now displays a generic error page instead of its content, rendering the record unavailable. Users cannot view the study details or related information until the error is resolved.SummaryDifference17%

- Check72 days agoChange DetectedA new page revision label, v3.6.4, was added in the page metadata and the previous label, v3.6.3, was removed.SummaryDifference0.1%

Stay in the know with updates to Clinical Trial of IL-2 + Nivolumab in RCC
Enter your email address, and we'll notify you when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.